^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210, INCSHR1210, SHR-1210, HR-301210
    Company:
    CG Invites, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. (PubMed, Adv Ther)
    Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.
    Review • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KDR (Kinase insert domain receptor)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Bavencio (avelumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    4d
    Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study (ChiCTR2500114600)
    P=N/A, N=150, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New trial
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • oxaliplatin • irinotecan • leucovorin calcium
    4d
    Hepatic Arterial Infusion Chemotherapy Combined with Camrelizumab and Lenvatinib for Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Study (ChiCTR2500113383)
    P=N/A, N=64, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New trial
    |
    Lenvima (lenvatinib) • AiRuiKa (camrelizumab)
    4d
    Neoadjuvant TACE Combined with Camrelizumab and Apatinib for Centrally Located Hepatocellular Carcinoma(NEO-CENTACT): A Single-Arm, Prospective, Exploratory Study (ChiCTR2500112222)
    P=N/A, N=40, Not yet recruiting, West China Hospital, Sichuan University; Sichuan University West China Hospital
    New trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    4d
    Optimization of immunotherapy strategies for locally advanced and metastatic gastric cancer under the guidance of CTCs and ctDNA (ChiCTR2500113727)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • docetaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    4d
    A prospective study of bipolar androgen followed by novel AR inhibitors combined with PD-1 inhibitors in the treatment of mCRPC (ChiCTR2600116595)
    P3, N=30, Recruiting, Beijing Hospital; Beijing Hospital
    New P3 trial
    |
    AiRuiKa (camrelizumab)
    4d
    Camrelizumab plus Rivoceranib as first-line maintenance therapy after Camrelizumab-Chemo induction in advanced esophageal squamous cell carcinoma: a prospective, single-arm, phase II clinical trial (ChiCTR2600116141)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    4d
    Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)
    P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • leucovorin calcium • Enshuxing (enlonstobart) • SYS6010
    4d
    An Exploratory Study on the Treatment of Anaplastic Thyroid Carcinoma with Camrelizumab Combined with Apatinib and Capecitabine (ChiCTR2500113785)
    P2, N=20, Completed, Sichuan Cancer Hospital; Sichuan Cancer Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine
    4d
    A Single-arm Phase II Clinical Trial evaluating Camrelizumab plus Capecitabine as Maintenance Therapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (ChiCTR2500111883)
    P2, N=26, Recruiting, The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University
    New P2 trial
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • capecitabine
    4d
    Camrelizumab Combined with Fruquintinib and Sodium Propionate Capsules for Late-Line Treatment of Advanced Metastatic Colorectal Cancer in a Phase II Study (ChiCTR2500112349)
    P2, N=38, Not yet recruiting, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    AiRuiKa (camrelizumab) • Fruzaqla (fruquintinib)
    4d
    Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy (ChiCTR2500113324)
    P2, N=79, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P2 trial
    |
    carboplatin • paclitaxel • docetaxel • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • irinotecan